Company profile

Intra-Cellular Therapies

Neuroscience-focused biopharma (Caplyta/lumateperone), acquired by Johnson & Johnson April 2025 for ~$14.6B

Privately held: no public share price (Delisted 2025-04-02 after Johnson & Johnson completed its acquisition of Intra-Cellular Therapies.) · USA

Assets

(3 total)
3Total Assets
1Approved
0Phase 3 / Filed
2Phase 1–2 / Early
4Diseases
Quick filter:
Showing 3 of 3 assets
Target & Modality
Lumateperone(Caplyta)
Approved
Serotonin 5-HT2A / dopamine D1-D2 receptorSmall molecule
Major Depressive DisorderSchizophrenia
ITI-1284
Phase 2
Dopamine D2/D3 and serotonin 5-HT1A receptorSmall molecule
Alzheimer's Disease
Lenrispodun (ITI-214)
Phase 2
PDE1Small molecule
Parkinson's Disease

Upcoming events

Research

Unlock the company readout calendar

Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.

Financial reports

Research

Unlock sourced financial history

Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.

Educational data tool. Figures are sourced from company filings and press releases: see each row's filing link. Share price is delayed (~15min) and refreshed periodically, not a real-time feed.